At least in our mouse models of pancreatic and prostate tumors, SGLT2 inhibitors reduce Me4FDG uptakes at normal plasma glucose levels indicating significant glucose uptake by SGLT2. This evidence concerns the gene SLC5A2 and prostate neoplasm.